Qureight, a Techbio company that promotes understanding of lungs and heart disease through the application of AI’s imaging and clinical data platform, announced today the Craig Rhodes appointment as head of corporate relationships to lead strategic bindings with pharmaceutical organizations, according to Qureight. Craig was a former director of Healthcare and Life Sciences in Nvidia.
In his new role, Craig will lead to securing and managing strategic relations with partners of pharmaceutical companies, from conception to delivery. Utilizing his deep know -how in completion of technology and the development of relationships, Craig will support the adoption and integration of the Qureight platform into clinical trials. Qureight deep learning images analysis and AI data analysis platform allow for the promotion of real knowledge from complex and varied health data, including scanning CTs, physiological data and blood -based where there are high unsatisfactory medical needs.
A very experienced AI leader in both great technology and starting ecosystem, Craig has over 25 years of experience and a proven history of innovation and transformation throughout the field. In his role in Nvidia, Craig’s leadership has contributed to the accelerated AI adoption in health care and discovery of drugs, mainly through the operation of Cambridge-1, the largest AI supercomputer in the United Kingdom. This initiative has allowed innovative research and set a new reference for GPU -powered workload, with partners such as GSK, Astrazeneca, King’s College London, Guy’s and St Thomas’ Hospital and Oxford Nanopore. Craig joins Qureight from Deepc, where he pioneered strategic partnerships with NHS to integrate AI imaging models into clinical work flows. Prior to his tenure at Deepc, Craig played critical roles in driving pathology and AI genomic initiatives in Intel, developing national healthcare systems in Oracle and contributing to the design of clinical paths for NHS in Map of Medicine.
Craig’s background, expertise and network will be invaluable to promote our strategy for building and strengthening the Pharma Partners network to increase commercial value for the company. The Craig reception in the group is a key part of our ongoing mission to promote understanding of lungs and heart disease, revolutionize clinical trials and accelerate the development of drugs through the integration of AI solutions. “
Muhuntan Thillai, MD, Co -founder and CEO, Qureight
Craig Rhodes, head of corporate relationships, Qureight, added: “The time it takes to pass a new drug through clinical trials can create a significant congestion in the process of developing medicines, defining the approval of new treatments with life -changing potential. Commitment to the utilization of technology to improve healthcare results.”
